Korbinian Berschneider

Therapeutic Area Director Breast Cancer at Daiichi Sankyo Germay - Medical Affairs & Clinical Development Leader

Germany

About

Mit über einem Jahrzehnt Erfahrung im medizinischen Bereich leite ich derzeit das Breast Cancer Medical Team bei Daiichi Sankyo Deutschland. Mein Fokus liegt auf der Entwicklung und Umsetzung von Strategien für die Markteinführung hochmoderner ADCs, die das Leben von Brustkrebspatientinnen positiv beeinflussen können. Ich stehe für eine psychologisch sichere Arbeitsumgebung und eine kollaborative Teamkultur als wesentliche Voraussetzungen für innovative Lösungen. Gemeinsam mit meinem Team strebe ich danach, lokale und globale Strategien zu formen, die den Erfolg unserer Produkte maximieren und den Patienten einen echten Mehrwert bieten. In meiner aktuellen Rolle arbeite ich aktiv daran, mit interdisziplinären Teams und innerhalb Allianzen Synergien zu schaffen und gemeinsame Ziele zu erreichen. Mein Verantwortungsbereich umfasst die Führung eines dynamischen Teams sowie die Zusammenarbeit mit regionalen und globalen Stakeholdern, um den Erfolg mehrerer hochkarätiger Produkteinführungen zu gewährleisten. Ich bringe meine Expertise in Marktzugang, klinischer Entwicklung und strategischer Planung ein, um sowohl die Patientenversorgung zu verbessern als auch die Ziele unseres Unternehmens zu verwirklichen.

Experience

  • Therapeutic Area Director Breast Cancer at Daiichi Sankyo Deutschland GmbH
    Dec 2023 - Present · 2 yrs 8 mos

    Leading the Daiichi Sankyo Breast Cancer Medical Team to deliver on strategy and execution for multiple high profile launches of best-in-class ADCs -Leadership of the Medical Breast Cancer Team in Germany including a field-based MSL team and an inhouse medical team -Build a high performing & psychological safe team in a fast growing organization -Shaping and Influencing local, regional and global launch strategies for high-profile ADC launches in Breast Cancer -Fostering collaboration in two different alliances to unite for common objectives to maximize synergies and reduce friction

  • Novartis (7 yrs 6 mos)
    • Country Coordinator Clinical Research Medical Advisor (CRMA) Germany
      Nov 2022 - Dec 2023 · 1 yr 2 mos

      Bridging the gap between clinical strategy, scientific excellence and clinical execution in clinical trial design & execution Leading >25 Clinical Research Medical Advisors in Germany in 13 Disease Areas Portfolio oversight over all Clinical Development trials in Novartis Germany Representing Clinical Development in local Medical Leadership as well as Region Europe Leadership teams Building a fit for purpose country clinical research organization during a major organizational transformation Setting focus and building structures to enhance clinical trial protocol fit, set-up speed and recruitment in Germany to make Germany the #1 country in Novartis in Clinical Trial KPIs Strategically influence global clinical trial designs to ensure optimal representation of German medical needs

    • Head Disease Area and MSL Respiratory & Allergy in Germany
      Mar 2021 - Nov 2022 · 1 yr 9 mos

      Reimagining Respiratory Medicine & Allergic Diseases through innovative clinical research, medical engagement & communication - Leading the German clinical research & medical affairs team and building "#OneTeam" to drive medical affairs strategy and execution - accountable for pre-Launch activities in severe Asthma, COPD and Food Allergy, early pipeline development in several rare respiratory diseases and in-market activities in Asthma and COPD - Create a curious, inspired, safe and empowering teamspace - Build on shared objectives and strategy driven decision making - External Focus with close exchange and collaboration with external opinion leaders and medical experts -------------------------------- Role responsibilities: Team lead for Medical Advisors, MSLs & Assistants in Respiratory & Allergy Strategic planning and oversight of medical affairs & clinical research in Germany  Budget responsibility for respiratory & allergy clinical research & medical affairs Steering global strategy in global medical affairs and clinical development boards Close cross functional collaboration with market access, marketing, regulatory affairs etc.

    • Disease Area Head Respiratory
      Sep 2018 - Mar 2021 · 2 yrs 7 mos

      Dedicated to excellent science, development and execution in Respiratory clinical research - Launching the first inhaled triple combination for Asthma & anti-IgE LCE-launch in CRSwNP during the COVID-19 Pandemic - leading pre-launch activities for several respiratory assets - assessing anti-viral and anti-inflammatory assets for repurposing during the COVID-19 pandemic - Leading the local clinical research team and building an inclusive, committed and competent team  - Strategy driven development of clinical development and research programs on global and local level - External Focus with close exchange and collaboration with external opinion leaders and medical experts - Excellence in execution of clinical trials with focus on time efficiency and high quality -------------------------------- Role responsibilities: Team lead for Medical Advisors within Respiratory Strategic planning and oversight of Phase Il-IV clinical trial programs in Germany  Responsible for building and managing relationships with key opinion leaders Budget responsibility for respiratory clinical research Member in global medical affairs and clinical development boards Close cross functional collaboration with market access, marketing, regulatory affairs etc.

  • PHD in molecular biology and translational medicine at Helmholtz Zentrum München
    Oct 2012 - Mar 2016 · 3 yrs 6 mos

    Deciphering the signaling pathways between mitochondria and the ubiquitin proteasome system and their role in disease and aging Graduation with distinction: "summa cum laude"

  • Research Internship at Karolinska institutet
    Jun 2010 - Aug 2010 · 3 mos

    Assessing the immunological effect of Interleukin-7 as and adjuvant for the tuberculosis vaccination with BCG. Member of the AMGEN Scholars Program